GlyCare™

GlyCare™ LNnT

GlyCare™ LNnT

Highly abundant neutral core HMO

Similar to 2'FL, LNnT promotes a healthy start in life for infants. LNnT is one of the most abundant neutral core HMO in human milk at ~0.5g/L1 with the following benefits : 

  • A protective role; preventing infection of the gut
  • Highly bifidogenic
  • Improve the gut barrier

GlyCare™ LNnT is clinically tested and can positively impact the health of infants, for example by reducing bronchitis and respiratory tract infections, and reducing usage of antibiotics and antipyretics2. GlyCare™ LNnT beneficially modulates the infant gut microbiota to a profile closer to that of breast fed through particularly an increase in bifidobacteria and reduction of certain undesirable bacteria3. LNnT plays a protective role by preventing adhesion of pathogenic organisms to intestinal cells4, promoting gut cell maturation5 and improving gut barrier function by decreasing gut permeability6, all of which help and support the infant. 

GlyCare™ LNnT also promotes digestive health in children and adults. GlyCare™ LNnT has been clinically proven safe, well tolerated and bifidogenic in children and adults7,8.

Currently, GlyCare LNnT is commercially available for use in infant formula, baby and kids nutrition and supplements as well as general digestive health applications in the following products:  

  • GlyCare LNnTL 9000 - Premium crystallized powder
  • GlyCare LNnT 9000HA - Hypoallergenic, Crystallized powder
  • GlyCare LNnT 8001 - Amorphous powder 

Please contact us for specific product data sheets on each product and other details you find necessary - click here

GlyCare LNnT is approved for sales in many markets including US, Europe, Middle East, Asia and South America. 

GlyCare LnNT is also available as Analytical Standard - click here.

 

[1] Erney, R. M., et al.,  2000. J Pediatr Gastroenterol Nutr: 30, 181-92. [2] Puccio, G., et al., 2017, J Pediatr Gastroenterol Nutr: 64, 624-631. [3] Steenhout et al., 2016, FASEB J 2016; 30 (suppl 1), 275.7 [4] Cravioto et al. 1991 J. Infect. Dis., 163, 1247-55. [5] Hester and Donovan, 2012, Food and Nutrition Sciences, 3, 1567-1576. [6] Holscher et al. 2014, J Nutr. 144, 586-91. [7] ClinicalTrials.gov, NCT02786160. [8] Elison et al. 2016, Br J Nutr, 116, 1356-1368.

GlyCare™ 2FL

Learn more
Our website uses cookies We will ask you to consent to our use of cookies in accordance with the terms of this policy read more
Ok